Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its ...
WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year
Stay updated with breaking news from Highly Potent. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at...
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9...
/PRNewswire/ -- The "Highly Potent API Market - A Global and Regional Analysis: Focus on Type, Type of Synthesis, Therapeutic Area, Type of Manufacturing, End...
/PRNewswire/ -- The "High Potent Medicines Conference" conference has been added to ResearchAndMarkets.com's offering. Looking and the current market scenario,...